0.0480CHF+6.67%Mkt Cap: 7.10M CHFP/E: —Last update: 2026-05-13
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enz…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-1.13
PEG—
P/B0.88
P/S41.96
EV/EBITDA-1.48
EV/Revenue22.90
EPS (TTM)-0.06
EPS (Forward)-0.04
Cash Flow & Leverage
FCF Yield-8.45%
FCF Margin-378.36%
Operating CF-5.37M CHF
CapEx (TTM)1.27K CHF
Net Debt/EBITDA0.88
Net Debt-2.15M CHF
Technical
SMA 500.0447 (+7.4%)
SMA 2000.0540 (-11.1%)
Beta1.86
S&P 52W Chg24.23%
Avg Vol (30d)230.96K
Avg Vol (10d)213.15K
Technical Indicators
RSI (14)53.0
MACD0.0005
MACD Signal0.0007
MACD Hist.-0.0002
BB Upper0.0512 CHF
BB Middle0.0473 CHF
BB Lower0.0434 CHF
BB Width16.58%
ATR (14)0.0043 CHF
Vol Ratio (20d)0.71x
52W Range
0.033628% of range0.0850
52W High0.0850 CHF
52W Low0.0336 CHF
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin1746.04%
Oper. Margin-1403.58%
ROE72.91%
ROA66.08%
Revenue Growth-15.00%
Earnings Growth—
Balance Sheet
Debt/Equity0.00
Current Ratio2.01
Quick Ratio1.91
Book Value/Sh0.0510 CHF
Cash/Share0.0190 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 26, 2022
Ownership
Shares Out.147.84M
Float92.72M
Insiders10.00%
Institutions1.11%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap7.10M CHF
Enterprise Value3.63M CHF
Revenue (TTM)158.54K CHF
Gross Profit-525.65K CHF
Net Income (TTM)7.06M CHF
Revenue/Share0.0020 CHF
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees2
Last Price0.0480 CHF
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0029850754